10-Q: Silexion Therapeutics Q1 2026 Financial Results

Silexion Therapeutics reports Q1 2026 financial results, highlighting ongoing clinical development of SIL204 and significant capital raising efforts to address going concern risks.

Summary

• Net loss for the three months ended March 31, 2026, was $2.7 million, compared to $1.7 million for the same period in 2025.
• Operating expenses increased to $2.7 million in Q1 2026 from $1.6 million in Q1 2025, driven by R&D costs for SIL204.
• Cash and cash equivalents were $2.4 million as of March 31, 2026, down from $6.0 million at year-end 2025.
• The company is in the development stage and has not yet generated revenue.
• Management has expressed substantial doubt about the company's ability to continue as a going concern, noting current funds are sufficient for only several months.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a high-risk situation due to the 'going concern' warning, significant cash depletion, and the necessity for continuous dilutive financing to maintain operations and listing status.

Positives

• Advanced operational readiness for clinical trials of lead candidate SIL204, expected to initiate in Q2 2026.
• Successfully raised $1.0 million in May 2026 through an induced warrant exercise transaction.
• Maintained Nasdaq listing compliance through strategic financing and reverse share splits.
• Expanded corporate footprint with the establishment of Silexion Therapeutics GmbH in Germany.

Negatives

• Significant increase in net loss to $2.7 million for the quarter.
• Substantial doubt regarding the company's ability to continue as a going concern.
• Cash reserves have depleted significantly, falling to $2.4 million as of March 31, 2026.
• Heavy reliance on continuous equity financing and warrant exercises to fund operations.

Risks

• Substantial doubt about the ability to continue as a going concern due to recurring losses and limited cash.
• Need for substantial additional funding, which may not be available on acceptable terms and could cause significant shareholder dilution.
• Clinical development of RNAi therapeutics is unproven and may never lead to marketable products.
• Potential for immediate delisting from Nasdaq if compliance with shareholders' equity or minimum bid price requirements is not maintained.
• Geopolitical instability in Israel, where management and employees are located, could impact operations.

Future Outlook

The company plans to initiate clinical trials for its lead candidate, SIL204, in the second quarter of 2026, contingent upon regulatory clearance. It intends to continue raising capital through the ATM facility and potential future equity offerings to fund operations and maintain Nasdaq compliance.

Management Comments

• Management acknowledges substantial doubt regarding the company's ability to continue as a going concern.
• Management believes current funds are sufficient for only several months from the date of the filing.
• Management maintains that the conversion of the Related Party Promissory Note was carried out in strict compliance with the note's requirements.

Industry Context

StockSavvy.ai notes that Silexion operates in the highly competitive and capital-intensive RNAi therapeutics space. The company's reliance on frequent dilutive financing is common for early-stage biotech firms, but its specific struggle to maintain Nasdaq listing requirements highlights the volatility and high risk associated with its current development stage.

Comparison to Industry Standards

• The company's cash runway is significantly shorter than typical clinical-stage biotech peers, which often aim for 18-24 months of liquidity.
• The reliance on ATM facilities and warrant inducement transactions is a standard, albeit aggressive, survival strategy for micro-cap biotech companies facing liquidity constraints.
• The focus on KRAS-driven cancers places the company in a crowded field with larger, better-capitalized competitors.

Corporate Governance

Legal Proceedings

• None.

Related Party Transactions

• The company has a Related Party Promissory Note with the Sponsor, with $1.229 million outstanding as of the date of the report.
• The Sponsor disputes the conversion of the promissory note into ordinary shares and has demanded repayment in full.

Stakeholder Impact

• Shareholders face significant dilution from ongoing equity financing and warrant exercises.
• Creditors and suppliers are subject to the company's liquidity risks.
• Employees face uncertainty regarding the company's long-term financial stability.

Next Steps

• Initiate human clinical trials for SIL204 in Q2 2026.
• Effect a 1-for-10 reverse share split in late May or early June 2026.
• Continue efforts to raise capital via the ATM facility and other potential offerings.
• Complete the dissolution of the inactive subsidiary, Moringa, by June 30, 2026.

Key Dates

Recommendation

The company is in a precarious financial position with a 'going concern' warning, minimal cash reserves, and a history of significant losses. The reliance on dilutive financing and the threat of Nasdaq delisting make this a high-risk investment unsuitable for most investors.

Keywords

Silexion Therapeutics, biotechnology, RNAi, KRAS, SIL204, oncology, clinical trials, Nasdaq, SLXN